Diaceutics (LON:DXRX) Shares Down 1.8% – Here’s Why

Diaceutics PLC (LON:DXRX) dropped 1.8% on Thursday . The stock traded as low as GBX 133 and last traded at GBX 133. Approximately 43,656 shares were traded during trading, a decline of 75% from the average daily volume of 176,776 shares. The stock had previously closed at GBX 135.50.

Analyst Ratings Changes

Separately, Canaccord Genuity Group raised their target price on Diaceutics from GBX 215 to GBX 216 and gave the company a “buy” rating in a research note on Thursday, June 4th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of GBX 215.50.

Diaceutics Price Performance

The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85. The business has a 50-day moving average price of GBX 149.98 and a two-hundred day moving average price of GBX 153.53. The company has a market capitalization of £112.56 million, a price-to-earnings ratio of 1,209.09 and a beta of 0.89.

Diaceutics (LON:DXRX) last posted its quarterly earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share (EPS) for the quarter. The business had revenue of GBX 3,844 million during the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. As a group, research analysts anticipate that Diaceutics PLC will post 1.0107919 EPS for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.